Skip to main content

Site notifications

Notice for palovarotene (Ipsen Pty Ltd)

Active ingredients
palovarotene
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Capsule with hard shell
Indication
To reduce the formation of heterotopic ossification (HO) in patients with fibrodysplasia (myositis) ossificans progressiva (FOP)
Therapeutic area
Musculoskeletal

Help us improve the Therapeutic Goods Administration site